G61
Conditions
Interventions
Group 1: Patients are followed longitudinally. Clinical data and biosamples are collected (see also study description).
Group 2: Subjects with polyneuropathies of other origins are observed longitudin
Sponsors
Charité - Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Patients with CIDP or CIDP variants (DADS, MADSAM, purely sensory/purely motor, focal courses) or other immune-mediated polyneuropathies [multifocal motor neuropathy, polyneuropathy of the rheumatic type or chronic inflammatory bowel diseases, chronic inflammatory axonal polyneuropathy (CIAP) , autoimmune (para)nodopathies Guillian Barré Syndrome, polyneuropathies in the context of monoclonal gammopathies of unclear significance, anti-MAG neuropathies] • Age- and sex-matched subjects with polyneuropathy of other origin (hereditary, diabetic/toxic origin) • control patients of the same age and gender with central demyelinating disease (multiple sclerosis) • Age- and sex-matched healthy subjects with no other underlying autoimmune-mediated disease or comorbidities • Ability to consent and written informed consent
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| activity of dealy life score | — |
Secondary
| Measure | Time frame |
|---|---|
| - Analysis of antibodies, proteins, RNA and DNA etc. in bio samples - Questionnaires on severity perception, quality of life, depression, fatigue and cognition - Electrophysiological investigations | — |
Countries
Germany
Contacts
Public ContactFrauke Stascheit
Charité - Universitätsmedizin Berlin
Outcome results
None listed